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ABSTRACT 
Objective: Low permeability of rosuvastatin calcium faces a problem of low bioavailability (absolute bioavailability 20%) as its permeation is the 
rate limiting factor. Rosuvastatin calcium is a selective competitive inhibitor of HMG-CoA reductase and it lowers plasma cholesterol level. Aspirin is 
an anti-platelet agent with half-life of 6-7 h. Frequency of dosing of both drugs is high to maintain the desired plasma drug concentration so it is 
selected to formulate a sustained release tablet of aspirin and rosuvastatin calcium, which release the drug in a sustained manner over a period of 
time by using various polymers and study the effect of polymers on the release pattern of both drugs. This approach will also enhance the residence 
time of rosuvastatin calcium at the absorption site and enhance permeation by the effect of the polymers used and this in turn will enhance 
bioavailability.  
Methods: Tablets contain aspirin plus rosuvastatin calcium were prepared by direct compression method. The sustained release of the tablets was 
obtained by using different polymers (xanthan gum, microcrystalline cellulose, HPMC K4M and chitosan) incorporated in the tablet and responsible 
for the release of both drugs from each tablet. Tablets were evaluated for weight variation, drug content, friability, hardness and thickness for all 
batches (F1 to F12). In-vitro dissolution was studied for all batches (F1 to F12) according to the type and ratio of each polymer used within these 
formulas i.e. (10 mg, 20 mg and 30 mg) respectively.  
Results: The release of aspirin and rosuvastatin calcium from sustained release tablets varied according to the type and amount (ratio) of each 
polymer used. After the 7 h release study; (F1, F2, F3) that uses xanthan gum as the sustain release polymer showed the most sustained 
formulations than other polymers. The sustained release of drugs from tablet enhanced by increasing the amount of polymer, so F3 for example, 
which contain 30 mg xanthan gum had most sustained release than F1 and F2 which contain (10 mg and 20 mg) of the polymer respectively, this 
due to polymer related viscosity, swelling and binding mechanisms.  
Conclusion: Using suitable polymer for sustained release will enhance the pharmacokinetics and efficacy of drugs and increase patient complains 
about combination therapy. 
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INTRODUCTION 
The majority of the discovered and existing drugs administered 
orally may face bioavailability problems because of many reasons 
such as poor dissolution, unpredicted absorption and inter-intra-
subject variation [1]. Developed and developing countries move 
towards a combination therapy used for the treatment of diseases 
requiring long-term therapy. Combination therapy has various 
advantages such as less dose-dependent side effects. Further, low 
dose combination of two different drugs decreases the clinical and 
metabolic side effects that occur with a maximal dosage of an 
individual component of the combined tablet and so dose of one 
component can be decreased [2].  
Oral sustained release dosage forms were the most commonly 
formulated and offer highest interesting in the area of novel drug 
delivery systems. Prolonging the gastric retention is desirable for 
achieving the therapeutic benefit of drugs that are absorbed in the 
stomach and small intestine or drugs are less soluble in or degraded 
by high pH they encounter at the distal part of the gastrointestinal 
tract (GIT). Sustain release and gastric retention mechanisms had 
the benefit of such drugs by improving their bioavailability, 
therapeutic efficacy and reduction of dose. These mechanisms had 
various pharmacokinetics advantages like maintenance of constant 
therapeutic levels over a prolonged period of time and so decrease 
in fluctuations in therapeutic levels [3]. The goal in designing a 
sustained delivery system to reduce the number of dosing and 
increase the effectiveness of the drugs by targeting at the site of 
action so reducing the dose required by providing this uniform drug 
delivery system. The sustained release mechanism is defined as a 
dosage form that release one or more drugs continuously in a 
predetermined pattern for a fixed period of time, either systemic or 
local [4]. In this approach drugs rosuvastatin calcium (RSC) and 
aspirin used to enhance combination therapy for patients with 
cardiovascular diseases and hypercholesterolemia and enhance the 
bioavailability of the drugs by sustaining release mechanism as 
compared to the single plane tablet for each one in the market. 
Polymers and their blends are used in the formulations to achieve 
sustained drug release from the dosage form.  
Most thoroughly investigated and used synthetic agents are 
hydroxyl propyl methyl cellulose (HPMC) and sodium 
carboxymethyl cellulose (NaCMC) [1]. The main adverse effects 
associated with Aspirin (acetylsalicylic acid) are the gastrointestinal 
disturbances and ulcer. Sustained release tablets of aspirin provide a 
more constant plasma drug concentrations with the less frequent 
administration, also could help lower the side effects to some 
degree. This could prolong its safe administration and improve 
patient compliance [5]. Unlike other statins, rosuvastatin calcium is 
hydrophilic. Low solubility and bioavailability of rosuvastatin 
calcium when taken orally as a tablet dosage form make the 
pharmacist develop a new dosage form to enhance dissolution and 
permeation and hence bioavailability of the drug when taken orally, 
so sustain release approach is used to enhance bioavailability of 
rosuvastatin calcium [6]. 
MATERIALS AND METHODS 
Materials 
Materials were used: Rosuvastatin calcium (Atra Pharmaceuticals, 
India), Aspirin (Samara drug industry, Iraq), Xanthan gum (HIMEDIA 
Laboratories, India), Microcrystalline cellulose (MCC) (Avecil pH 
102) (Sigma Aldrich CO, USA), hydroxyl propyl methyl cellulose 
(HPMC) K4M (HIMEDIA Laboratories, India),Chitosan (HIMEDIA 
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Laboratories, India), Talc (Afco., india), Polyvinylpyrrolidone (PVP) 
(Riedel De Haen AG Seelze, Hannover, Germany), Lactose (Riedel-
deltaen, Germany) and magnesium stearate (HIMEDIA Laboratories, 
India). 
Methods 
Preparation of tablets 
In keeping with the concept of reducing the cost of production, a 
simple method was used. A direct compressed formulation consisting 
of two principal components was formed. These two components are 
the drug and the polymer that retards release of the drugs.  
With appropriate choice of the polymer, compaction of the blend by 
direct compression would lead to the formation of a matrix tablet 
[7]. Sustain release tablets were prepared by direct compression 
method by mixing the ingredients with different ratios (drugs, 
polymer, lactose and PVP) after formation of a mass it compressed 
by single punch tablet machine. Formulas from 1 to 12 were 
prepared and each 3 formulas contained different polymer (as 
shown in table 1). Different polymers were used to evaluate the 
effect of polymer on the physical properties of the blend and on the 
formed tablets and the release of both drugs from matrix tablets 
formed. 
Evaluation of blends 
Prior to the compression into tablets, the powder was evaluated for 
properties like the angle of repose by funnel method, bulk density, 
tapped density, Carr’s index and Hausner’s ratio (as shown in table 
2) [8]. 
Density 
The tapped bulk density (TBD) and loose bulk density (LBD) were 
calculated by using the following equations:  
Tapped bulk density =weight of the powder 
final volume
 ……. Equation 1 
Loose bulk density =weight of the powder 
initial volume
 …. .Equation 2 
Compressibility: The compressibility index was determined by the 
Carr’s compressibility index. 
Carr’s compressibility index = [(TBD−LBD)×100
TBD
] ……. Equation 3 
Hausner’s ratio = TBD 
LBD
 ……… Equation 4 
Evaluation of tablet 
Prepared tablets were evaluated for some important parameters like 
weight variation, drug content, tablet friability, tablet hardness, 
tablet thickness (As shown in table 3) and In-vitro dissolution test 
which carried out by using type II (paddle type) dissolution 
apparatus for 7 h for each formula [2]. 
Weight variation 
Twenty tablets were selected at random for each formula and the 
average weight was calculated. Not more than 2 of individual 
weights of tablets out from the average weight by more than the 
percentage deviation and none deviate by more than twice the 
percentage [8]. The official limit of percentage deviation is (7.5%) 
because the average weight of the tablet lies in the range between 
(130-324 mg). 
Drug content 
The total amount of each drug within the tablet for different 
formulas was analyzed by using a UV spectrophotometer by suitable 
dilution in volumetric flasks using solvents and read the solution at 
230 nm for aspirin and 242 nm for rosuvastatin calcium [2]. The 
amount of each drug in each tablet was measured according to a 
valid calibration curve for each drug. 
Friability, Hardness and thickness 
Twenty tablets are taken for friability evaluation for each formula; 
the accepted value must be between 0.5%-1%. Friability measured 
by using Roche friabilator at 25 rpm for 4 min. The friability value 
for each formula was obtained by using the following equation [9]: 
F% = W initial−W final
W initial
 × 100………… Equation 5 
Hardness was performed for 10 tablets for each formula by using the 
Monsanto hardness tester and the average value was obtained [10]. 
Vernier caliper scale was used for determination thickness for 
tablets. Five tablets for each formula were taken and the average 
thickness for each formula in millimeter was obtained [2, 8]. 
In-vitro drug release 
The In-vitro drug release of rosuvastatin calcium and aspirin were 
done by using dissolution apparatus type II (paddle type). Paddle 
speed 50 rpm in 900 ml buffer solution (pH 6.8) at 37 oC using UV-
Visible spectroscopy to determine the amount of drug release after a 
determined period of time. 
The procedure last 7 h long (n=7). Samples of (10 ml) were 
withdrawn every one hour and replaced by the same amount of 
fresh buffer (pH 6.8) to maintain sink condition and release drug 
concentration was measured by UV spectroscopy at 230 nm and 242 
nm respectively. [6,11] 
The release of drugs was affected by the type and amount of polymer 
used in each formula from F1 to F12. 
Kinetics of drug releases profile 
The cumulative amount of rosuvastatin calcium release and aspirin 
release from tablet were fitted to different models (zero order 
kinetics, first order kinetics, Higuchi model, and Korsmeyer-Peppas 
model) which used to characterize the kinetics of each drug release. 
Statistical analysis  
To investigate the significance of difference between the results 
from the studied formulations, the one-way analysis of variance test 
was used. The level of significance was set at (α 0.05), and less than 
this value was considered to be statistically significant. 
RESULTS AND DISCUSSION 
Twelve formulas were formulated and each formula contained 
different amount or type of polymer. Study of blend properties and 
tablet characteristics were done (as shown in table 2 and table 3). 
From the results of table 2, angle of repose determination showed 
good flow for all the formulas except formula 6 showed passable flow.  
Compressibility index showed F1 and F8 had excellent 
compressibility while F4 had good compressibility and F3 had 
passable compressibility. The other formulas showed decrease in 
compressibility to poor state and this due to the composition of the 
polymers also used a type of polymer affect the compressibility of 
the blend. A Hausner ratio of less than 1.25 indicates a good flow, 
while greater than 1.5 indicates poor flow. A Hausner ratio between 
1.25 and 1.5 added glidant normally improves flow [12]. 
Weight variation calculations were within the accepted value 
according to the USP for all formulas. Not more than two of the 
individual weights out from the average weight by more than the 
percentage deviation and none deviate by more than twice the 
percentage. As shown in table 3, drug content for all formulas for 
aspirin and rosuvastatin calcium was within the accepted values. 
Friability for all formulas was lie within the accepted range (0.5%-
1%). Hardness for all formulas gave an idea about the sustain matrix 
tablet as noticed for the values which were lied between 5.1 kg/cm2 
to 7.6 kg/cm2 (as shown in table 3) [12]. All the tablet formulations 
showed acceptable properties and complied with pharmacopeial 
specifications for thickness values [12]. 
In-vitro dissolution studies showed that two factors are affecting the 
release of drugs from tablet formula in (pH 6.8) buffer solution. All 
formulas were evaluated for 7 h in dissolution apparatus type II. 
Samples taken were measured by UV spectroscopy. Each data point 
in the dissolution profile represents the mean of three 
determinations (n=3). 
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1-Effect of type of polymer on release profile 
Four polymers used for the preparation of tablets (Xanthan gum, MCC, 
HPMC K4M and Chitosan). Each polymer had its hydrophilic-lipophilic 
properties which affect drug release also the mechanism of dissolution 
(Swelling, pH dependent, floating and viscosity effects) [13, 14]. 
Formulas (1, 4, 7, and 10) contain Xanthan gum, MCC, HPMC K4M 
and Chitosan respectively. All had the same amount of polymer in 
each tablet (10 mg). 
As shown in fig. 1 which demonstrate the effect of type of polymer 
on the release profile of aspirin. F4 had the higher release (71% 
after 7 h) which contained MCC and the lower sustain release was 
recorded for F1 (53% after 7 h) which contained xanthan gum. 
F7 which contain HPMC K4M was 56.1% and F10 was 64.3% which 
contain chitosan after 7 h dissolution respectively. 
For rosuvastatin calcium, fig. 2 demonstrates the effect of type of 
polymer on the release profile. F4 had the higher release (70.7% 
after 7 h) (*P<0.05) which contained MCC and the lower sustain 
release was recorded for F1 (50% after 7 h) (*P<0.05) which 
contained xanthan gum. 
F7 which contain HPMC K4M was 52.6% and F10 was 59.8% which 
contain chitosan after 7 h dissolution respectively. 
Although HPMC hydration and gel formation are not affected by 
changes in pH, the pH of the dissolution media affects the release of 
drugs from HPMC matrices.  
Attempts have been made to quantify the influences of the solutions 
containing chloride and phosphate ions at different strengths on 
dissolution rates from HPMC release sustain tablets [15]. 
Drug solubility along with HPMC K4M also affects drug release. 
HPMC K4M showed the most sustain release of drugs at pH 1.2 due 
to the low solubility of drugs and lower dissolution of the 
hydrophilic polymer HPMC so the release was higher at (pH 6.8) 
buffer solution [16]. 
The deformation mechanism and the physicochemical properties of 
the hydrophilic polymer MCC are the main factors for its 
performance. MCC plasticity together with its relatively low bulk 
density, high hygroscopicity and high surface area explains its 
unique binding properties. MCC is more lubricant sensitive, strain 
rate sensitive and cohesive. All these factors produce higher release 
for the drugs from tablet than other polymers [17]. 
Chitosan polymer is a polycationic in nature, well known for its 
chelating properties. So, the reactions of the cations with the 
negatively charged components, either ions or molecules lead to the 
formation of a network by ionic bridges between polymeric chains.  
Ionic interactions between the negative charges of the crosslinker 
(drug) and cationic groups of Chitosan are the main interactions 
inside the network. Their nature depends on the type of crosslinker, 
this lead to electrostatic interactions formed between the positively 
charged ammonium groups (-NH4+) of chitosan and the anionic 
groups of the drug. The properties of pH dependent drug delivery 
systems can be controlled by the conditions during preparation. 
Systems generally exhibit pH-sensitive swelling and drug release by 
diffusion through their porous structure [18]. 
Drug release is mainly influenced by ionic interactions between 
chitosan chains, which depend primarily on the crosslinking density, 
which set during the formation of the network. An increase in cross-
linking density induces a decrease in swelling and decrease in pH-
sensitivity and so improving the stability of the network, and results in 
the decreased drug release. When pH decreases the cross-linking 
density becomes lesser, that lead to increase the drug release [18]. 
Xanthan gum in aqueous solution has been well established for 
many years. The disordered random coil conformation loses the 
ability to form a gel while the ordered elongated conformation is 
able to so. The formation rate of an ordered structure in xanthan 
gum has long been known to increase dramatically with increasing 
concentration of added salt. It has been proved that the presence of 
salt in the medium elevates the transition temperature (Tm). In 
addition, it has also been found that the hydrodynamic volume of 
this exopolysaccharide molecule changes with the ionic strength 
because of the changes in intramolecular electrostatic repulsion by 
ions. All these phenomena should reflect the viscosity and gelation 
properties of this polymer. The results of the viscosity 
measurements in a different type of ionic strength showed that the 
viscosity of moderately dilute xanthan gum in aqueous media is 
influenced by the ionic strength [13]. 
 
Table 1: Preparation of different formulas of sustained release tablets* 
Ingredient Formulations 
 (mg/tab.) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Aspirin 100 100 100 100 100 100 100 100 100 100 100 100 
Rosuvastatin 20 20 20 20 20 20 20 20 20 20 20 20 
Xanthan gum 10 20 30 - - - - - - - - - 
MCC - - - 10 20 30 - - - - - - 
HPMC K4M - - - - - - 10 20 30 - - - 
Chitosan - - - - - - - - - 10 20 30 
Talc 5 5 5 5 5 5 5 5 5 5 5 5 
PVP 10 10 10 10 10 10 10 10 10 10 10 10 
Lactose 40 30 20 40 30 20 40 30 20 40 30 20 
Mg stearate 5 5 5 5 5 5 5 5 5 5 5 5 
*Total weight of the tablet 190 mg 
 
Table 2: Evaluation parameters for the blend 
Formula Angle of repose (Өo) Bulk density (g/ml) Tapped density (g/ml) Compressibility index Hausner’s ratio 
F1 22±2 0.45±0.045 0.5±0.026 10±1 1.11±0.4 
F2 21±2.1 0.5±0.042 0.65±0.031 23±1.4 1.3±0. 41 
F3 26±1.4 0.4±0.033 0.5±0.024 20±1.9 1.25±0.45 
F4 23±1.8 0.35±0.029 0.42±0.036 16.6±2.1 1.2±0.51 
F5 27±2.3 0.53±0.048 0.72±0.041 26.4±2.9 1.35±0.4 
F6 33±2 0.5±0.044 0.78±0.033 35.9±2.5 1.56±0.53 
F7 21±1.7 0.4±0.045 0.53±0.021 24.5±1.5 1.33±0.51 
F8 25±2.1 0.55±0.053 0.6±0.034 8.3±1.04 1.1±0.19 
F9 29±1.9 0.3±0.04 0.39±0.027 31.8±1.5 1.3±0.32 
F10 24±1.88 0.39±0.05 0.54±0.041 27.7±1.2 1.38±0.49 
F11 28±2.3 0.35±0.04 0.49±0.025 28.57±1.6 1.4±0.33 
F12 30±2.1 0.5±0.048 0.68±0.042 26.4±1.1 1.36±0.4 
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Drug content of ASP 
%±SD  
(n=3) 












F1 189.1±1.6 99%±0.3 98.7%±0.21 0.6 5.2±0.2 3.1±0.021 
F2 188.3±1.5 98.2%±0.23 99.5%±0.34 0.54 6.1±0.3 4.2±0.03 
F3 189±2.1 101%±0.15 100.4%±0.3 0.4 6.7±0.33 4.9±0.022 
F4 192±1.9 99.3%±0.4 97.0%±0.31 0.52 4.9±0.24 4.3±0.035 
F5 191±2.4 98.6%±0.36 99.0%±0.24 0.41 5.4±0.43 4.5±0.015 
F6 188±2.3 98.2%±0.11 102.7%±0.21 0.53 6.3±0.25 4.8±0.017 
F7 189±2.5 99.5%±0.24 98.2%±0.27 0.67 5.5±0.11 3.8±0.024 
F8 188.7±1.7 102%±0.14 99.4%±0.43 0.73 6.2±0.14 4.2±0.02 
F9 191.4±2.4 101.6%±0.17 98.4%±0.37 0.5 7.6±0.24 4.8±0.049 
F10 193±1.5 99%±0.26 101.7%±0.33 0.65 5.1±0.13 4.2±0.022 
F11 192.5±1.54 98.7%±0.34 101.4%±0.25 0.58 6.3±0.17 4.8±0.036 
F12 191.7±2.3 99.8%±0.14 100.4%±0.32 0.62 7.4±0.22 5.2±0.04 
 
2-Effect of amount of polymer on release profile 
Each polymer used in 3 different amounts (10 mg, 20 mg, 30 mg) for 
aspirin and rosuvastatin release, as shown in fig. 3 and fig. 4 in the 
use of xanthan gum in F1, F2 and F3 respectively.  
The release was retarded and sustained from matrix tablet by an 
increase in the amount of polymer in the tablet. F3 had a lower 
release (*P<0.05) than F1 and F2 respectively. These results 
indicated that increase the amount of polymer in the tablet provide 
more gelation, which inhibits the release of effective substance [19]. 
This effect was observed with the use of other polymers like MCC, 
HPMC K4M, and chitosan polymers as shown in fig. 5 and 6 for MCC 
and fig. 7 and 8 for HPMC K4M and fig. 9 and 10 for chitosan 
respectively. 
Kinetics of drug releases profile 
In-vitro release profiles for prepared formulas (F1, F4, F7 and 
F10) were applied to different kinetic models (zero order, first 
order, Higuchi model and Korsmeyer-Peppas models). The rate 
constant, as well as the high correlation coefficient and the best-
fitted line, were obtained in order to find out the mechanism of 
drug release for aspirin and for rosuvastatin calcium, the release 
kinetics data of the formulas are given in (table 4 and table 5) 
respectively [6]. 
The highest correlation coefficient (R2) resulted with 
Korsmeyer-Peppas model combined with zero order in case of 
F1, F7 and F10 which indicates that the drug release is ruled by 




Fig. 1: In-vitro dissolution for studying the effect of type of 
polymer on the release profile of aspirin in 6.8 buffer solution 
(F1 contain xanthan gum, F4 contain MCC, F7 contain HPMC 
K4M and F10 contain chitosan) 
 
 
Fig. 2: In-vitro dissolution for studying the effect of type of 
polymer on the release profile of rosuvastatin calcium in 6.8 
buffer solution (F1 contain xanthan gum, F4 contain MCC, F7 
contain HPMC K4M and F10 contain chitosan) 
 
In Korsmeyer-Peppas model, the drug release kinetics in a most 
befitting manner, where the values of the diffusion exponent (n) 
were more than 0.5 (0.706-1.097) confirming that the formulations 
followed non-Fickian diffusion kinetics. 
This indicates that the release mechanism shifted from diffusion-
controlled to an anomalous transport (non Fickian) in which both 
diffusion and erosion is governing the release [20]. 
 
 
Fig. 3: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of aspirin from tablets 
contain xanthan gum polymer in 6.8 buffer (F1:10 mg xanthan 
gum, F2:20 mg xanthan gum and F3:30 mg xanthan gum) 
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Fig. 4: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of rosuvastatin calcium from 
tablets contain xanthan gum polymer in 6.8 buffer (F1:10 mg 
xanthan gum, F2:20 mg xanthan gum and F3:30 mg xanthan gum) 
 
 
Fig. 5: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of aspirin from tablets 
contain MCC polymer in 6.8 buffer (F4:10 mg MCC, F5:20 mg 
MCC and F6:30 mg MCC) 
 
 
Fig. 6: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of rosuvastatin calcium 
from tablets contain MCC polymer in 6.8 buffer (F4:10 mg MCC, 
F5:20 mg MCC and F6:30 mg MCC) 
 
Fig. 7: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of aspirin from tablets 
contain HPMC K4M polymer in 6.8 buffer (F7:10 mg HPMC K4M, 
F8:20 mg HPMC K4M and F9:30 mg HPMC K4M) 
 
 
Fig. 8: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of rosuvastatin calcium 
from tablets contain HPMC K4M polymer in 6.8 buffer (F7:10 
mg HPMC K4M, F8:20 mg HPMC K4M and F9:30 mg HPMC K4M) 
 
 
Fig. 9: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of aspirin from tablets 
contain chitosan polymer in 6.8 buffer (F10:10 mg chitosan, 
F11:20 mg chitosan and F12:30 mg chitosan) 
F6 
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Table 4: Kinetic modeling for different formulas for aspirin release 
Formula 
Code 
Zero order First order Higuchi model Koresmeyer-Peppas model 
k ° R2 k1 R2 kH R2 kKp R2 N 
F1 7.641  0.9926 0.098 0.9737 16.732 0.8007 7.519 0.9912 1.010 
F4 11.321 0.9013 0.176 0.9842 25.360 0.9291 18.451 0.9901 0.706 
F7 8.242 0.9919 0.098 0.9737 18.113 0.8172 8.687 0.9909 0.969 
F10 9.181 0.9987 0.125 0.9660 20.171 0.8192 9.484 0.9986 0.981 
 
Table 5: Kinetic modeling for different formulas for rosuvastatin release 
Formula 
Code 
Zero order First order Higuchi model Koresmeyer-Peppas model 
k ° R2 k1 R2 kH R2 kKp R2 N 
F1 7.064 0.9894 0.088 0.9606 15.383 0.7692 6.002 0.9925 1.097 
F4 10.931 0.9626 0.164 0.9761 7.181 0.7955 14.944 0.9888 0.812 
F7 7.674 0.9962 0.099 0.9811 16.841 0.8151 7.913 0.9957 0.982 
F10 8.577 0.9964  0.114 0.9767 18.856 0.8239 9.126 0.9966 0.963 
 
 
Fig. 10: In vitro dissolution for studying the effect of amount of 
polymer on the In-vitro release profile of rosuvastatin calcium 
from tablets contain chitosan polymer in 6.8 buffer (F10:10 mg 
chitosan, F11:20 mg chitosan and F12:30 mg chitosan) 
 
CONCLUSION 
Direct compression method can be used rather than wet granulation 
because it is an easier, simplified and economical method of 
manufacturing of tablets. This is widely used and a better process of 
manufacturing. The hydrophobic polymer matrix tablet is a 
promising approach to achieve appropriate sustained release 
dosage. Xanthan gum showed the most sustain release profile for 
aspirin and rosuvastatin calcium than other polymers due to the pH 
of the medium and mechanism of drug release. MCC polymer 
showed higher release in this study. Sustain release is a useful 
approach for less dosing interval and for combination therapy. 
Other studies can be done in preparation of sustaining matrix tablet 
with mixed polymers which give extra benefit for modifying the 
release of drugs and manipulate the time of release, but 
compatibility study for polymers and polymer-drugs should be done 
using IR spectroscopy. Also other pH buffer media for dissolution 
can be used for study pH effect on the polymer used and its effect on 
the release profile of drugs. 
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